Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
← catalyst calendarSponsored by Tenaya Therapeutics (industry) · TNYA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
15estimated
Sites
7
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-26 | actual | When the study began enrolling |
| Primary completion | 2026-05-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Arrhythmogenic Right Ventricular Cardiomyopathy
Intervention
- Genetic: TN-401
Primary outcomes
what the primary-completion date above is the date OFNumber and severity of Adverse Events over the course of the study.
measured 52 weeks
Number of Serious Adverse Events related to study drug.
measured 5 years
Permalink · TNYA's whole pipeline · Catalyst calendar · Every registered study · What changed